生命科学资讯

Altimmune eyes phase 3 MASH trial as weight loss deepens

Chutes & Ladders—Pfizer RNA leader runs to Replicate

Cybin alters state to become Helus Pharma for Nasdaq trip

Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners

Senators point fingers over who blocked the rare disease voucher reauthorization

Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail

Biomarin buying rare disease company Amicus for $4.8B

Why Waters Corporation stock remains on buy lists - Risk Management & Risk Controlled Stock Alerts - Bölüm Sonu Canavarı

Galapagos TYK2 drug hits goal in one trial, misses in another

Biotech company Illumina loses venture building head Casas - - Global Venturing

Maintaining sexual identity in adult flies is an ongoing commitment

Aging-related peroxisomal dysregulation disrupts intestinal stem cell differentiation through alterations of very long-chain fatty acid oxidation

Whalen Wealth Management Inc. Has $1.64 Million Stock Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat

Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration

Chia Tai Tianqing Pharmaceutical patents new AKT1 inhibitors

Aché Laboratórios Farmacêuticos divulges new compounds for respiratory disorders

Haisco Pharmaceutical describes new IL-17A production inhibitors

New platinum complex prodrugs disclosed in Beijing Changping Laboratory patent

Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

Catalent handed two Form 483s, including for Sarepta gene therapy site